Common use of Authorization of Notes Clause in Contracts

Authorization of Notes. The Issuer will authorize the issue and sale of (a) $200,000,000 aggregate principal amount of its 4.11% Series A Senior Notes due April 17, 2026 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 aggregate principal amount of its 4.31% Series B Senior Notes due April 17, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1.1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1.1(b). Certain capitalized and other terms used in this Agreement are defined in Schedule A and, for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Issuer Company will authorize the issue and sale of (a) $200,000,000 100,000,000 aggregate principal amount of its 4.112.41% Senior Guaranteed Green Notes, Series A, due July 15, 2028 (the “Series A Notes”) and (b) $50,000,000 aggregate principal amount of its 2.84% Senior Notes Guaranteed Notes, Series B, due April 17July 15, 2026 2031 (the “Series B Notes”, together with the Series A Notes, the “Notes,” such term to include any such notes as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 aggregate principal amount of its 4.31% Series B Senior Notes due April 17, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”). The Series A Notes shall be substantially in the form forms set out in Schedule 1.1(a1(a) and Schedule 1(b), respectively, with such changes therefrom, if any, as may be approved by the Series B Notes shall be substantially in Purchasers and the form set out in Schedule 1.1(b)Company. Certain capitalized and other terms used in this Agreement are defined in Schedule A and, for purposes A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall govern.Agreement unless otherwise specified. Terreno Realty LLC Agreement Note Purchase

Authorization of Notes. The Issuer Company will authorize the issue and sale of (a) $200,000,000 aggregate principal amount of its 4.11Guaranteed Senior Notes, of which $150,000,000 aggregate principal amount shall be its 3.98% Series A D Guaranteed Senior Notes due April 17July 6, 2026 (the “Series D Notes”), and $50,000,000 aggregate principal amount shall be its 3.66% Series E Guaranteed Senior Notes due September 15, 2023 (the “Series E Notes”; the Series D Notes and the Series E Notes, as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 aggregate principal amount of its 4.31% Series B Senior Notes due April 17, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”). The Series A Notes shall be substantially in the form respective forms set out in Schedule 1.1(a1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1.1(b1(b). Certain capitalized and other terms used in this Agreement are defined in Schedule A and, for purposes A. References to a “Schedule” or an “Exhibit” are references to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall governAgreement unless otherwise specified.

Authorization of Notes. The Issuer Company will authorize the issue and sale of (a) $200,000,000 100,000,000 aggregate principal amount of its 4.11senior notes consisting of (a) $50,000,000 aggregate principal amount of its 2.97% Senior Notes, Series A Senior Notes 2021A, due April 17October 30, 2026 2051 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 50,000,000 aggregate principal amount of its 4.313.07% Senior Notes, Series 2021B, due October 28, 2061 (the “Series B Senior Notes due April 17Notes” and together with the Series A Notes, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including the “Notes” such term shall also include any such notes Series A Notes or Series B Notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”13 of this Agreement). The Series A Notes shall be substantially in the form set out in Schedule 1.1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1.1(bExhibit 1(a) and Exhibit 1(b), respectively, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule A andB; references to a “Schedule” or an “Exhibit” are, for purposes unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall governAgreement unless otherwise specified.

Authorization of Notes. The Issuer Company will authorize the issue and sale of (ai) $200,000,000 125,000,000 aggregate principal amount of its 4.113.99% Series A Senior Notes due April 17January 13, 2026 2023 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (bii) $200,000,000 100,000,000 aggregate principal amount of its 4.314.51% Series B Senior Notes due April 17January 13, 2029 2027 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, ”; and together with the Series A Notes, collectively, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1.1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1.1(b1(a) and Schedule 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A and, for purposes A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall governAgreement unless otherwise specified.

Authorization of Notes. The Issuer Company will authorize the issue and sale of (a) $200,000,000 75,000,000.00 aggregate principal amount of its 4.11% Senior Series A Senior Notes at 4.40% due April 17November 12, 2026 2020 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 25,000,000.00 aggregate principal amount of its 4.31% Senior Series B Senior Notes at 5.19% due April 17November 12, 2029 2023 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with ”). The Series A Notes and the Series A Notes, collectively, B Notes shall be collectively referred to as the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1.1(a) and the 1A. The Series B Notes shall be substantially in the form set out in Schedule 1.1(b). 1B. Certain capitalized and other terms used in this Agreement are defined in Schedule A and, for purposes B. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall governAgreement unless otherwise specified.

Authorization of Notes. The Issuer will authorize the issue and sale of (ai) $200,000,000 100,000,000 aggregate principal amount of its 4.114.12% Senior Notes, Series A, due June 30, 2021 (the “Series A Notes”) and (ii) $150,000,000 aggregate principal amount of its 4.58% Senior Notes, Series B, due June 30, 2024 (the “Series B Notes”). The Series A Notes due April 17and the Series B Notes are collectively referred to herein as the “Notes,” such term to include any amendments, 2026 (as amended, restated restatements or otherwise modified other modifications from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 aggregate principal amount of its 4.31% Series B Senior Notes due April 17, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1.1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1.1(b1(a) and Schedule 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A and, for purposes A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall governAgreement unless otherwise specified.

Authorization of Notes. The Issuer Company will authorize the issue and sale of (a) $200,000,000 100,000,000 aggregate principal amount of its 4.11senior notes consisting of (a) $50,000,000 aggregate principal amount of its 5.56% Senior Notes, Series A Senior Notes 2023A, due April 17September 28, 2026 2033 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 50,000,000 aggregate principal amount of its 4.315.85% Senior Notes, Series 2023B, due October 30, 2053 (the “Series B Senior Notes due April 17Notes”; and together with the Series A Notes, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including the “Notes” such term shall also include any such notes Series A Notes or Series B Notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”13 of this Agreement). The Series A Notes shall be substantially in the form set out in Schedule 1.1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1.1(bExhibit 1(a) or Exhibit 1(b), respectively, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule A andB; references to a “Schedule” or an “Exhibit” are, for purposes unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall governAgreement unless otherwise specified.

Authorization of Notes. The Issuer Company will authorize the issue and sale of (a) $200,000,000 75,000,000 aggregate principal amount of its 4.113.70% Senior Guaranteed Notes, Series A, due November 30, 2030 (the “Series A Notes”) and (b) $55,000,000 aggregate principal amount of its 3.82% Senior Notes Guaranteed Notes, Series B, due April 17November 30, 2026 2031 (the “Series B Notes”, and together with the Series A Notes, the “Notes”, each as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 aggregate principal amount of its 4.31% Series B Senior Notes due April 17, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”). The Series A Notes shall be substantially in the form forms set out in Schedule 1.1(a) 1-A and the Series B Notes shall be substantially in the form set out in Schedule 1.1(b)1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B. References to “series” of Notes shall refer to the Series A andNotes and the Series B Notes or all, for purposes as the context may require. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall governAgreement unless otherwise specified.

Authorization of Notes. The Issuer Company will authorize the issue and sale of (a) $200,000,000 100,000,000 aggregate principal amount of its 4.11% Series A B Senior Notes due April 17October 1, 2026 2013 (as amendedthe “Series B Notes”), restated or otherwise modified from time (b) $50,000,000 aggregate principal amount of its Series C Senior Notes due October 1, 2015 (the “Series C Notes”) and (c) $100,000,000 aggregate principal amount of its Series D Senior Notes due October 1, 2018 (the “Series D Notes” and, together with the Series B Notes and the Series C Notes, collectively, the “Notes”, such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 aggregate principal amount of its 4.31% Series B Senior Notes due April 17, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”). The Series A B Notes, Series C Notes and Series D Notes shall be substantially in the form forms set out in Schedule 1.1(a) Exhibit 1A, Exhibit 1B and the Series B Notes shall be substantially in the form set out in Schedule 1.1(b)Exhibit 1C, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A andB; and references to a “Schedule” or an “Exhibit” are, for purposes of unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Issuer Company will authorize the issue and sale of (a) $200,000,000 100,000,000 aggregate principal amount of its 4.11senior notes, of which $50,000,000 aggregate principal amount shall be its 3.73% Series A Senior Notes due April 1715, 2026 2023 (the “Series A Notes”) and $50,000,000 aggregate principal amount shall be its 3.88% Series B Senior Notes due April 15, 2025 (the “Series B Notes”) (the Series A Notes and the Series B Notes, as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the each a “Series A Notes”) Note” and (b) $200,000,000 aggregate principal amount of its 4.31% Series B Senior Notes due April 17, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”). The Series A Notes shall be substantially in the form respective forms set out in Schedule 1.1(aExhibits 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1.1(b1(b). Certain capitalized and other terms used in this Agreement are defined in Schedule A andB. References to a “Schedule” or an “Exhibit” are, for purposes unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall governAgreement unless otherwise specified.

Authorization of Notes. The Issuer Company will authorize the issue and sale of (a) $200,000,000 50,000,000 aggregate principal amount of its 4.114.23% Senior Guaranteed Notes, Series A due September 1, 2022 (the “Series A Notes”) and (b) $50,000,000 aggregate principal amount of its 4.65% Senior Notes Guaranteed Notes, Series B due April 17October 13, 2026 2027 (the “Series B Notes” and together with the Series A Notes, such term to include any such notes as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 aggregate principal amount of its 4.31% Series B Senior Notes due April 17, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1.1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1.1(b)1-A and Schedule 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A and, for purposes A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall governAgreement unless otherwise specified.

Authorization of Notes. The Issuer Company will authorize the issue and sale of (a) $200,000,000 75,000,000 aggregate principal amount of its 4.113.91% Series 2019-A Senior Notes due April 17June 25, 2026 2029 (the “Series 2019-A Notes”). The Series 2019-A Notes together with each Series of Additional Notes which may from time to time be issued pursuant to the provisions of Section 2.2, in each case as may be amended, restated or otherwise modified from time to time pursuant to the provisions of Section 17 and including are collectively referred to herein as the “Notes” (such term shall also include any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 aggregate principal amount of its 4.31% Series B Senior Notes due April 17, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”). The Series 2019-A Notes shall be substantially in the form set out in Schedule 1.1(a) Exhibit 1 with such changes therefrom, if any, as may be approved by the Purchasers and the Series B Notes shall be substantially in the form set out in Schedule 1.1(b)Company. Certain capitalized and other terms used in this Agreement are defined in Schedule A andB; and references to a “Schedule” or an “Exhibit” are, for purposes of unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Issuer Company will authorize the issue and sale of (ai) $200,000,000 150,000,000 aggregate principal amount of its 4.112.72% Senior Notes, Series A, due February 27, 2020 (the “Series A Notes”), and (ii) $350,000,000 aggregate principal amount of its 3.29% Senior Notes, Series B, due February 27, 2023 (the “Series B Notes”). The Series A Notes due April 17and the Series B Notes are collectively referred to herein as the “Notes,” such term to include any amendments, 2026 (as amended, restated restatements or otherwise modified other modifications from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 aggregate principal amount of its 4.31% Series B Senior Notes due April 17, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1.1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1.1(b1(a) and Schedule 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A and, for purposes B. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall governAgreement unless otherwise specified.

Authorization of Notes. The Issuer will authorize the issue and sale of (ai) $200,000,000 50,000,000 aggregate principal amount of its 4.114.98% Senior Guaranteed Notes, Series A, due October 1, 2024 (the “Series A Notes”) and (ii) $50,000,000 aggregate principal amount of its 4.98% Senior Notes Guaranteed Notes, Series B, due April 17July 1, 2026 (the “Series B Notes”). The Series A Notes and Series B Notes are collectively referred to herein as amendedthe “Notes”, restated such term to include any amendments, restatements or otherwise modified modifications from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 aggregate principal amount of its 4.31% Series B Senior Notes due April 17, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1.1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1.1(b1(a) or Schedule 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A and, for purposes A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall governAgreement unless otherwise specified.

Authorization of Notes. The Issuer will authorize the issue and sale of (ai) $200,000,000 100,000,000 aggregate principal amount of its 4.114.08% Senior Notes, Series A Senior Notes A, due April 17September 30, 2026 (the “Series A Notes”) and (ii) $100,000,000 aggregate principal amount of its 4.24% Senior Notes, Series B, due December 28, 2028 (the “Series B Notes”). The Series A Notes and the Series B Notes are collectively referred to herein as amendedthe “Notes,” such term to include any amendments, restated restatements or otherwise modified other modifications from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 aggregate principal amount of its 4.31% Series B Senior Notes due April 17, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1.1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1.1(b1(a) and Schedule 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A and, for purposes A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall governAgreement unless otherwise specified.

Authorization of Notes. The Issuer Company will authorize the issue and sale of (a) $200,000,000 75,000,000 aggregate principal amount of its 4.11senior notes consisting of (a) $25,000,000 aggregate principal amount of its 2.87% Senior Notes, Series A Senior Notes 2020D, due April 17September 1, 2026 2050 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A D Notes”) and (b) $200,000,000 50,000,000 aggregate principal amount of its 4.312.97% Senior Notes, Series B Senior Notes 2020E, due April 17September 1, 2029 2060 (as amendedthe “Series E Notes” and together with the Series D Notes, restated or otherwise modified from time to time pursuant to Section 17 and including the “Notes” such term shall also include any such notes Series D Notes or Series E Notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”13 of this Agreement). The Series A D Notes and the Series E Notes shall be substantially in the form set out in Schedule 1.1(aExhibit 1(a) and Exhibit 1(b), respectively, with such changes therefrom, if any, as may be approved by the Series B Notes shall be substantially in Purchasers and the form set out in Schedule 1.1(b)Company. Certain capitalized and other terms used in this Agreement are defined in Schedule A andB; references to a “Schedule” or an “Exhibit” are, for purposes unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall governAgreement unless otherwise specified.

Authorization of Notes. The Issuer will authorize the issue and sale of (ai) $200,000,000 75,000,000 aggregate principal amount of its 4.114.10% Senior Guaranteed Notes, Series A, due June 13, 2025 (the “Series A Notes”) and (ii) $100,000,000 aggregate principal amount of its 4.27% Senior Notes Guaranteed Notes, Series B, due April 17June 13, 2026 2028 (as amendedthe “Series B Notes” and together with the Series A Notes, restated the “Notes,” such term to include any amendments, restatements or otherwise modified modifications from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series A Notes”) and (b) $200,000,000 aggregate principal amount of its 4.31% Series B Senior Notes due April 17, 2029 (as amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Series B Notes,” and, together with the Series A Notes, collectively, the “Notes”). The Series A Notes shall be substantially in the form set out in Schedule 1.1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1.1(b)1-A and 1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A and, for purposes A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement, the rules of construction set forth in Section 22.4 shall governAgreement unless otherwise specified.